Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies

Bioconjugate Chemistry

Volumn 21, Issue 7, 2010, Pages 1264-1270

  Su, Yu Cheng ^a,b   Chen, Bing Mae ^b   Chuang, Kuo Hsiang ^c   Cheng, Tian Lu ^c   Roffler, Steve R ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; DOXORUBICIN; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3.3; MONOCLONAL ANTIBODY AGP4; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; BIOTINYLATION; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN;

EID: 77954874072     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc100067t     Document Type: Article

References (41)

1. Ensor, C. M., Holtsberg, F. W., Bomalaski, J. S., and Clark, M. A. (2002) Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo Cancer Res. 62, 5443-50
2. Sun, X., Yang, Z., Li, S., Tan, Y., Zhang, N., Wang, X., Yagi, S., Yoshioka, T., Takimoto, A., Mitsushima, K., Suginaka, A., Frenkel, E. P., and Hoffman, R. M. (2003) In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5′-phosphate supplementation Cancer Res. 63, 8377-83
3. Yamamoto, Y., Tsutsumi, Y., Yoshioka, Y., Nishibata, T., Kobayashi, K., Okamoto, T., Mukai, Y., Shimizu, T., Nakagawa, S., Nagata, S., and Mayumi, T. (2003) Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity Nat. Biotechnol. 21, 546-52
4. Baker, D. P., Lin, E. Y., Lin, K., Pellegrini, M., Petter, R. C., Chen, L. L., Arduini, R. M., Brickelmaier, M., Wen, D., Hess, D. M., Chen, L., Grant, D., Whitty, A., Gill, A., Lindner, D. J., and Pepinsky, R. B. (2006) N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model Bioconjugate Chem. 17, 179-88
5. Zappe, H., Snell, M. E., and Bossard, M. J. (2008) PEGylation of cyanovirin-N, an entry inhibitor of HIV Adv. Drug Delivery Rev. 60, 79-87
6. Kronman, C., Cohen, O., Mazor, O., Ordentlich, A., Raveh, L., Velan, B., and Shafferman, A. (2009) Next generation OP-bioscavengers: A circulatory long-lived 4-PEG hypolysine mutant of F338A-HuAChE with optimal pharmacokinetics and pseudo-catalytic characteristics. Chem. Biol. Interact., 10.1016/j.cbi.2009.12.004.
7. Freitas, D. D., Spencer, P. J., Vassao, R. C., and Abrahao-Neto, J. (2010) Biochemical and biopharmaceutical properties of PEGylated uricase Int. J. Pharm. 387, 215-222
8. Zhang, Y., Sun, C., Kohler, N., and Zhang, M. (2004) Self-assembled coatings on individual monodisperse magnetite nanoparticles for efficient intracellular uptake Biomed. Microdevices 6, 33-40
9. Lee, H., Yu, M. K., Park, S., Moon, S., Min, J. J., Jeong, Y. Y., Kang, H. W., and Jon, S. (2007) Thermally cross-linked superparamagnetic iron oxide nanoparticles: synthesis and application as a dual imaging probe for cancer in vivo J. Am. Chem. Soc. 129, 12739-45
10. Kim, S., Lim, Y. T., Soltesz, E. G., De Grand, A. M., Lee, J., Nakayama, A., Parker, J. A., Mihaljevic, T., Laurence, R. G., Dor, D. M., Cohn, L. H., Bawendi, M. G., and Frangioni, J. V. (2004) Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping Nat. Biotechnol. 22, 93-7
11. Gao, X., Cui, Y., Levenson, R. M., Chung, L. W., and Nie, S. (2004) In vivo cancer targeting and imaging with semiconductor quantum dots Nat. Biotechnol. 22, 969-76
12. Heathcote, E. J., Shiffman, M. L., Cooksley, W. G., Dusheiko, G. M., Lee, S. S., Balart, L., Reindollar, R., Reddy, R. K., Wright, T. L., Lin, A., Hoffman, J., and De Pamphilis, J. (2000) Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis N. Engl. J. Med. 343, 1673-80
13. Reddy, K. R., Wright, T. L., Pockros, P. J., Shiffman, M., Everson, G., Reindollar, R., Fried, M. W., Purdum, P. P., 3rd, Jensen, D., Smith, C., Lee, W. M., Boyer, T. D., Lin, A., Pedder, S., and DePamphilis, J. (2001) Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C Hepatology 33, 433-8
14. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M., and Albrecht, J. K. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358, 958-65
15. Goffin, V. and Touraine, P. (2002) Pegvisomant. Pharmacia Curr. Opin. Invest. Drugs (Thomson Sci.) 3, 752-7
16. Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. O., Hanauer, S. B., McColm, J., Bloomfield, R., and Sandborn, W. J. (2007) Maintenance therapy with certolizumab pegol for Crohn's disease N. Engl. J. Med. 357, 239-50
17. Molineux, G. (2004) The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta) Curr. Pharm. Des. 10, 1235-44
18. Lyman, G. H. (2005) Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action Expert Opin. Biol. Ther. 5, 1635-46
19. Gordon, A., Fleagle, J., Guthrie, D., Parkin, D., Gore, M., and Lacave, A. (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J. Clin. Oncol. 19, 3312
20. Park, J. (2002) Liposome-based drug delivery in breast cancer treatment Breast Cancer Res. 4, 95-99
21. Gaberc-Porekar, V., Zore, I., Podobnik, B., and Menart, V. (2008) Obstacles and pitfalls in the PEGylation of therapeutic proteins Curr. Opin. Drug Discovery Dev. 11, 242
22. Yang, Z., Ke, J., Hayes, M., Bryant, M., and Tse, F. (2009) A sensitive and high-throughput LC-MS/MS method for the quantification of pegylated-interferon-alpha (2a) in human serum using monolithic C (18) solid phase extraction for enrichment. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci.
23. Zamboni, W., Ramalingam, S., Friedland, D., Edwards, R., Stoller, R., Strychor, S., Maruca, L., Zamboni, B., Belani, C., and Ramanathan, R. (2009) Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies Clin. Cancer Res. 15, 1466-1472
24. Cheng, T. L., Cheng, C. M., Chen, B. M., Tsao, D. A., Chuang, K. H., Hsiao, S. W., Lin, Y. H., and Roffler, S. R. (2005) Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles Bioconjugate Chem. 16, 1225-31
25. Cheng, T. L., Wu, P. Y., Wu, M. F., Chern, J. W., and Roffler, S. R. (1999) Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM Bioconjugate Chem. 10, 520-8
26. Kurfurst, M. M. (1992) Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis Anal. Biochem. 200, 244-8
27. Graham, M. L. (2003) Pegaspargase: a review of clinical studies Adv. Drug Delivery Rev. 55, 1293-302
28. Panetta, J. C., Gajjar, A., Hijiya, N., Hak, L. J., Cheng, C., Liu, W., Pui, C. H., and Relling, M. V. (2009) Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia Clin. Pharmacol. Ther. 86, 651-8
29. Silverman, L. B., Supko, J. G., Stevenson, K. E., Woodward, C., Vrooman, L. M., Neuberg, D. S., Asselin, B. L., Athale, U. H., Clavell, L., Cole, P. D., Kelly, K. M., Laverdiere, C., Michon, B., Schorin, M., Schwartz, C. L., O'Brien, J. E., Cohen, H. J., and Sallan, S. E. (2009) Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia Blood 7, 1351-1353
30. Ng, E. W., Shima, D. T., Calias, P., Cunningham, E. T., Jr., Guyer, D. R., and Adamis, A. P. (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease Nat. Rev. Drug Discovery 5, 123-32
31. Booth, C. and Gaspar, H. B. (2009) Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID) Biologics 3, 349-58
32. Liu, P., Santisteban, I., Burroughs, L. M., Ochs, H. D., Torgerson, T. R., Hershfield, M. S., Rawlings, D. J., and Scharenberg, A. M. (2009) Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient Clin. Immunol. 130, 162-74
33. Burke, R. S. and Pun, S. H. (2008) Extracellular barriers to in Vivo PEI and PEGylated PEI polyplex-mediated gene delivery to the liver Bioconjugate Chem. 19, 693-704
34. Regehly, M., Greish, K., Rancan, F., Maeda, H., Bohm, F., and Roder, B. (2007) Water-soluble polymer conjugates of ZnPP for photodynamic tumor therapy Bioconjugate Chem. 18, 494-9
35. Prencipe, G., Tabakman, S. M., Welsher, K., Liu, Z., Goodwin, A. P., Zhang, L., Henry, J., and Dai, H. (2009) PEG branched polymer for functionalization of nanomaterials with ultralong blood circulation J. Am. Chem. Soc. 131, 4783-7
36. Cosmi, B. (2009) ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent Curr. Opin. Mol. Ther. 11, 322-8
37. Hong, R. L. and Tseng, Y. L. (2001) Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity Cancer 91, 1826-33
38. Bailon, P., Palleroni, A., Schaffer, C. A., Spence, C. L., Fung, W. J., Porter, J. E., Ehrlich, G. K., Pan, W., Xu, Z. X., Modi, M. W., Farid, A., Berthold, W., and Graves, M. (2001) Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C Bioconjugate Chem. 12, 195-202
39. Wang, Y. S., Youngster, S., Grace, M., Bausch, J., Bordens, R., and Wyss, D. F. (2002) Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications Adv. Drug Delivery Rev. 54, 547-70
40. Curran, M. P. and Goa, K. L. (2002) Pegfilgrastim Drugs 62, 1207-13
41. Chuang, K., Tzou, S., Cheng, T., Kao, C., Tseng, W., Shiea, J., Liao, K., Wang, Y., Chang, Y., and Huang, B. (2010) Measurement of poly(ethylene glycol) by cell-based anti-poly (ethylene glycol) ELISA Anal. Chem. 82, 2355-2362